

## 10.4 SUMMARY TABLE

### A. For nivolumab 2-weekly:

#### SBRT prior to C3; first evaluation after C5

	All patients			
	Pre-study	D -14 to -1	C1D1	C2D1
Informed consent	•	•		
Demographics, medical Hx, performance status	•			
Imaging (CT or PET-CT)	• (max 4 weeks prior to randomisation)			
Randomisation		•		
Fecal sample			•	
Liquid biopsy			•	
CPI			•	•
AE			•	•
QoL			•	

	C3D -6	C3D -4 or -3	C3D -1	C3D1	C4D1	C5D1	C5D +1 to 14	Every Evaluation (consultation after imaging)
<b>Arm A</b>								
Liquid biopsy	•			•				•
Radiotherapy fraction*	•	•	•					
CPI				•	•	•		
AE	•			•	•	•	•	• (until 3 months after end radiotherapy)
QoL								• (at first evaluation and every 6 months thereafter)
Imaging (CT or PET-CT)							•	
<b>Arm B</b>								
Liquid biopsy				•				•
CPI				•	•	•		
Imaging (CT or PET-CT)							•	
AE				•	•	•	•	• (until 3 months after end radiotherapy)
QoL								• (at first evaluation and every 6 months thereafter)

**B. For nivolumab 4-weekly:  
SBRT prior to C2; first evaluation after C3**

	All patients		
	Pre-study	D -14 to -1	C1D1
Informed consent	•	•	
Demographics, medical Hx, performance status	•		
Imaging (CT or PET-CT)	• (max 4 weeks prior to randomisation)		
Randomisation		•	
Fecal sample			•
Liquid biopsy			•
CPI			•
AE			•
QoL			•

	C2D -6	C2D -4 or -3	C2D -1	C2D1	C3D1	C3D +1 to 14	Every Evaluation (consultation after imaging)
<b>Arm A</b>							
Liquid biopsy	•			•			•
Radiotherapy fraction*	•	•	•				
CPI				•	•		
AE	•			•	•	•	• (until 3 months after end radiotherapy)
QoL							• (at first evaluation and every 6 months thereafter)
Imaging (CT or PET-CT)						•	
<b>Arm B</b>							
Liquid biopsy				•			•
CPI				•	•		
Imaging (CT or PET-CT)						•	
AE				•	•	•	• (until 3 months after end radiotherapy)
QoL							• (at first evaluation and every 6 months thereafter)

**C. For pembrolizumab or atezolizumab 3-weekly:  
SBRT prior to C3; first evaluation after C4**

	All patients			
	Pre-study	D -14 to -1	C1D1	C2D1
Informed consent	•	•		
Demographics, medical Hx, performance status	•			
Imaging (CT or PET-CT)	• (max 4 weeks prior to randomisation)			
Randomisation		•		
Fecal sample			•	
Liquid biopsy			•	
CPI			•	•
AE			•	•
QoL			•	

	C3D -6	C3D -4 or -3	C3D -1	C3D1	C4D1	C4D +5 to 20	Every Evaluation (consultation after imaging)
<b>Arm A</b>							
Liquid biopsy	•			•			•
Radiotherapy fraction*	•	•	•				
CPI				•	•		
AE	•			•	•	•	• (until 3 months after end radiotherapy)
QoL							• (at first evaluation and every 6 months thereafter)
Imaging (CT or PET-CT)						•	
<b>Arm B</b>							
Liquid biopsy				•			•
CPI				•	•		
Imaging (CT or PET-CT)						•	
AE				•	•	•	• (until 3 months after end radiotherapy)
QoL							• (at first evaluation and every 6 months thereafter)